Published in Eur J Pharmacol on February 17, 2006
The evolution of vertebrate opioid receptors. Front Biosci (Landmark Ed) (2009) 1.05
Endogenous opiates and behavior: 2006. Peptides (2007) 0.92
Analgesia in amphibians: preclinical studies and clinical applications. Vet Clin North Am Exot Anim Pract (2011) 0.83
Nociceptin produces antinociception after spinal administration in amphibians. Pharmacol Biochem Behav (2008) 0.81
Comparison of buprenorphine and butorphanol analgesia in the eastern red-spotted newt (Notophthalmus viridescens). J Am Assoc Lab Anim Sci (2009) 0.76
The pharmacokinetics of remifentanil. J Clin Anesth (1996) 1.53
Effect of continuous spinal remifentanil infusion on behaviour and spinal glutamate release evoked by subcutaneous formalin in the rat. Br J Anaesth (1998) 1.45
Remifentanil update: clinical science and utility. CNS Drugs (2004) 1.33
Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. Anesthesiology (1997) 1.23
Alternatives to the use of mammals for pain research. Life Sci (1992) 1.21
Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues. J Pharmacol Exp Ther (1991) 1.14
Serum esterase inhibition in birds: a nondestructive biomarker to assess organophosphorus and carbamate contamination. Arch Environ Contam Toxicol (1992) 1.05
Analgesic potency of mu and kappa opioids after systemic administration in amphibians. J Pharmacol Exp Ther (1994) 1.01
Relative analgesic potency of mu, delta and kappa opioids after spinal administration in amphibians. J Pharmacol Exp Ther (1996) 1.01
Supraspinal administration of opioids with selectivity for mu-, delta- and kappa-opioid receptors produces analgesia in amphibians. Eur J Pharmacol (1997) 0.96
Morphine-induced analgesia and explosive motor behavior in an amphibian. Brain Res (1983) 0.96
Opioid research in amphibians: an alternative pain model yielding insights on the evolution of opioid receptors. Brain Res Brain Res Rev (2004) 0.95
Initial clinical experience with remifentanil, a new opioid metabolized by esterases. Anesth Analg (1995) 0.94
Selective opioid receptor agonist and antagonist displacement of [3H]naloxone binding in amphibian brain. Eur J Pharmacol (2000) 0.92
Spinal administration of selective opioid antagonists in amphibians: evidence for an opioid unireceptor. Life Sci (1999) 0.92
Early nociceptive events influence the temporal profile, but not the magnitude, of the tonic response to subcutaneous formalin: effects with remifentanil. J Pharmacol Exp Ther (1997) 0.88
Selective opioid agonist and antagonist competition for [3H]-naloxone binding in amphibian spinal cord. Brain Res (2000) 0.88
Acetylcholinesterase and butyrylcholinesterase activities in brain and plasma of freshwater teleosts: cross-species and cross-family differences. Comp Biochem Physiol B Biochem Mol Biol (2003) 0.88
Pseudo-cholinesterase in the central nervous system of the frog. Nature (1956) 0.86
Detection of acute tolerance to the analgesic and nonanalgesic effects of remifentanil infusion in a rabbit model. Anesth Analg (2003) 0.84
Remifentanil for obstetric analgesia and anesthesia: a review of the literature. Acta Anaesthesiol Belg (2005) 0.82
Continuous intrathecal administration of shortlasting mu opioids remifentanil and alfentanil in the rat. Anesthesiology (1996) 0.82
Serum "B" esterases as a nondestructive biomarker for monitoring the exposure of reptiles to organophosphorus insecticides. Ecotoxicol Environ Saf (1997) 0.81
An animal model for surgical anesthesia and analgesia: characterization with isoflurane anesthesia and remifentanil analgesia. Anesth Analg (2003) 0.80
Remifentanil. Curr Opin Crit Care (2001) 0.78
Seasonal variations in acetylcholine content and the levels of cholinergic enzymes in the alimentary tract and heart of Rana esculenta L. J Auton Nerv Syst (1992) 0.78
Histochemical characterization of cholinesterase activity in the frog brain with special reference to its localization on the wall of blood vessels. Histochem J (1976) 0.77
Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.83
Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.73
Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res (2004) 1.59
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg (2007) 1.54
Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol (2005) 1.53
Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg (2005) 1.49
Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol (2004) 1.43
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys (2007) 1.28
Evaluation of internal lung motion for respiratory-gated radiotherapy using MRI: Part I--correlating internal lung motion with skin fiducial motion. Int J Radiat Oncol Biol Phys (2004) 1.23
Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. Int J Radiat Oncol Biol Phys (2012) 1.21
Radiation injury of the lung after three-dimensional conformal radiation therapy. AJR Am J Roentgenol (2002) 1.18
Accumulation of the common mitochondrial DNA deletion induced by ionizing radiation. FEBS Lett (2004) 1.13
Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2003) 1.12
A deformable-model approach to semi-automatic segmentation of CT images demonstrated by application to the spinal canal. Med Phys (2004) 1.08
Semiautomated four-dimensional computed tomography segmentation using deformable models. Med Phys (2005) 1.06
Volumetric modulated arc planning for lung stereotactic body radiotherapy using conventional and unflattened photon beams: a dosimetric comparison with 3D technique. Radiat Oncol (2011) 1.05
Correlation of gross tumor volume excursion with potential benefits of respiratory gating. Int J Radiat Oncol Biol Phys (2004) 1.04
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys (2003) 1.03
Imaging of the patient with non-small cell lung cancer. Radiology (2005) 0.99
Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys (2005) 0.97
Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J (2004) 0.96
Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys (2004) 0.95
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg (2005) 0.94
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys (2003) 0.92
The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells. J Neuroimmunol (2007) 0.91
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys (2004) 0.91
Assessment of lung tumor motion and setup uncertainties using implanted fiducials. Int J Radiat Oncol Biol Phys (2007) 0.91
Assessment of tissue oxygen tension: comparison of dynamic fluorescence quenching and polarographic electrode technique. Crit Care (2002) 0.90
Characterization of mu, kappa, and delta opioid binding in amphibian whole brain tissue homogenates. J Pharmacol Exp Ther (2002) 0.90
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys (2004) 0.89
Intensity-modulated radiation therapy for mesothelioma: impact of multileaf collimator leaf width and pencil beam size on planning quality and delivery efficiency. Int J Radiat Oncol Biol Phys (2005) 0.88
Functional lung imaging in thoracic cancer radiotherapy. Cancer Control (2008) 0.87
Evaluation of internal lung motion for respiratory-gated radiotherapy using MRI: Part II-margin reduction of internal target volume. Int J Radiat Oncol Biol Phys (2004) 0.87
Predicting response to clinical radiotherapy: past, present, and future directions. Cancer Control (2008) 0.86
Radiation injury to the liver after intensity-modulated radiation therapy in patients with mesothelioma: an unusual CT appearance. AJR Am J Roentgenol (2005) 0.84
Dosimetric benefits of respiratory gating: a preliminary study. J Appl Clin Med Phys (2004) 0.84
Treatment planning for lung cancer: traditional homogeneous point-dose prescription compared with heterogeneity-corrected dose-volume prescription. Int J Radiat Oncol Biol Phys (2003) 0.84
Beta-funaltrexamine inhibits inducible nitric-oxide synthase expression in human astroglial cells. J Neuroimmune Pharmacol (2008) 0.84
Dual regulation of mu opioid receptors in SK-N-SH neuroblastoma cells by morphine and interleukin-1β: evidence for opioid-immune crosstalk. J Neuroimmunol (2010) 0.81
Target definition and contouring in carcinoma of the lung and esophagus. Rays (2004) 0.80
Effects of quantum noise in 4D-CT on deformable image registration and derived ventilation data. Phys Med Biol (2013) 0.78
Predicting radiosensitivity using DNA end-binding complex analysis. Clin Cancer Res (2004) 0.78
Tumor oxygenation and acidification are increased in melanoma xenografts after exposure to hyperglycemia and meta-iodo-benzylguanidine. Radiat Res (2003) 0.77
A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function. Eur J Pharmacol (2008) 0.77
Compensator-based intensity-modulated radiation therapy for malignant pleural mesothelioma post extrapleural pneumonectomy. J Appl Clin Med Phys (2008) 0.77
Quality assurance evaluation of delivery of respiratory-gated treatments. J Appl Clin Med Phys (2004) 0.77
DNA-PK and ATM are required for radiation-enhanced integration. Radiat Res (2002) 0.77
Outcomes and patterns of failure in bronchial carcinoid tumors. Int J Radiat Oncol Biol Phys (2003) 0.77
High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res (2005) 0.76
Radiosensitivity is predicted by DNA end-binding complex density, but not by nuclear levels of band components. Radiother Oncol (2004) 0.76
Β-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes. Neurochem Int (2013) 0.76
Evolution and faith: empathy is misplaced. Science (2008) 0.75
Analysis of incidental radiation dose to uninvolved mediastinal/supraclavicular lymph nodes in patients with limited-stage small cell lung cancer treated without elective nodal irradiation. Med Dosim (2011) 0.75
Personalized treatment approaches in radiation oncology: the future is now. Cancer Control (2008) 0.75
Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus? Gastrointest Endosc (2009) 0.75
Uncertainties in physical and biological targeting with radiation therapy. Rays (2004) 0.75